Format

Send to

Choose Destination
ASAIO J. 2007 Jul-Aug;53(4):460-3.

A case series describing the use of argatroban in patients on extracorporeal circulation.

Author information

1
Critical Care Medicine, C. S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan 48109, USA.

Abstract

Anticoagulation for extracorporeal life support (ECLS) is routinely achieved using heparin, which can be difficult in patients suspected of having heparin-induced thrombocytopenia. We describe a case series of five patients in which we used argatroban, a direct thrombin inhibitor, as an alternative to heparin for systemic anticoagulation during ECLS in patients suspected to have heparin-induced thrombocytopenia. Argatroban was used to achieve target systemic anticoagulation for activate clotting times between 210 and 230. Duration of argatroban use while on ECLS ranged from 6 to 184 hours. Argatroban dosage ranged from 0.2 to 3.5 microg/kg/min. Activated clotting times showed good agreement with aPTT. In conclusion, we illustrate that argatroban is a reasonable alternative to heparin anticoagulation for patients requiring ECLS.

PMID:
17667231
DOI:
10.1097/MAT.0b013e31805c0d6c
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center